Title: MEDICINE AND HEALTH IN THE TROPICS Plenary Session 3
1MEDICINE AND HEALTH IN THE TROPICSPlenary
Session 3 The Pharmaceutical Industrys RD
Drive and the issue of Tropical diseases 13
of September 2005
- Dr Pierre Le Sourd
- Leem President
2The issue of Tropical Diseases
- Definition
- Neglected infectious diseases that
disproportionately affect poor and marginalized
populations (TDR Special Program for Research
and Training in Tropical Diseases) - Current disease portfolio
TDR Disease Category 1 Emerging or
uncontrolled disease 2 Control strategy
available, but disease burden persists 3
Control strategy effective / Elimination
planned
Source World Health Report, 2004 DALYs -
Disability Adjusted Life Years (the number of
healthy years of life lost due to premature death
and disability)
3What is the Pharmaceutical Industry doing about
it ??Drug Companies part of the solution
instead of the issue
4Medicines existbut dont reach the patients in
need
- Most essential medicines are off-patent and
inexpensivehowever over 50 of populations in
Least Developed Countries lack regular access to
these products
Source IFPMA, Septembre 2004
5What are the real barriers ?
- Poverty
- Lack of public health infrastructure
- Lack of human resources
- Lack of manufacturing capability
- High tariffs on medicines
- Political denial
6Successful interventions supported by Drug
Companies (1)
- In last decade, global companies have become
critical contributors to numerous programs and
initiatives targeting health needs of the poor - In 2003, the value of donations by major
companies matched the US AID Global Budget for
Health - 3,7 billion over last 5 years
7Successful interventions supported by Drug
Companies (2)
- Examples of concrete actions
- Malaria
- In 2001, Novartis formed a partnership with WHO
to provide Coartem at no profit in developing
countries - Sanofi-Aventis launched a Specific Program
Impact Malaria to develop new treatments, new
therapeutic strategies, educational campaign and
to provide drugs at price, not loss, not
profit - Achievements Pilot projects in South Africa
resulted with outstanding health outcomes - Malaria cases reduced by 86
- Hospital admissions for malaria reduced by 82
- Malaria deaths decreased by 87
- Tuberculosis
- In South Africa, a huge involvement of
Sanofi-Aventis - Rifafour a combination of 4 medicines
commercialized to enable better compliance - A specific training program of 15 million
developed DOT Supporters (DOT Directly
Observed Treatment) for Health agents - Ambitions
- Building of 9 Training centers
- 100,000 Health agents trained
8Successful interventions supported by Drug
Companies (3)
- Examples of concrete actions
- Leishmaniasis
- Ampules of Glucantime (Sanofi-Aventis) provided
at no profit - Onchocerciasis
- 40 million doses of Mectizan (Merck) donated
annually in 34 countries - Trachoma
- 16 million treatments donated in 11 countries
- More than 80 million of Zithromax (Pfizer)
donated - Leprosy
- 35 million donated in multi-drug treatment
(Novartis) - Achievements
- About 13 million people cured over the past 15
years, while some 2-3 million people have been
protected from developing deformities - Lymphatic Filariasis
- 6 billion treatments of albendazole (GSK) planned
to be donated - 20 million treatments of Mectizan (Merck) donated
- Achievements
- 80 million people have received treatment
9Successful interventions supported by Drug
Companies (4)
- HIV/AIDS reference
- To increase access to ARVs in developing
countries, a huge involvement of the
Pharmaceutical Industry - 564 million in 2002
- Involvement in International Programs
- ONUSIDA
- ACCESS thanks to significant price discounts,
more than 330,000 patients in developing
countries received ARVs by the end of September
2004 - Pharmaceutical Initiatives
- Determine Donation Program (Abott), Secure the
Future (BMS), African Comprehensive HIV/Aids
Partnership (MerckCo), International HIV/Aids
Health Literacy Grants Program (Pfizer) - Health agents Training, equipments supply,
prevention technical aids, health education
10New or improved treatments needed
Source IFPMA, Septembre 2004
11Drug resistance is widespreadthe example of
Malaria
12What about new drugs and vaccines ? (1)
- Quantum leap in Research is coming
- RD is at a crossroad
- Development of Biotech Products
- 2003 40 of New Molecular Entities
- 2010 around 100 New Molecular Entities expected
- could deliver major breakthroughs
- leading to new hope for Tropical Diseases
13What about new drugs and vaccines ? (2)
- New dynamics in RD for Neglected Diseases
- Establishment of dedicated research centers by
major companies and increasing not-for-profit
approach to RD for neglected diseases - Creation of a RD efforts database of IFPMA
members - Growing number of product development public
private partnerships (PPPs) - Proliferation of RD players, including public
research institutes, academia, major pharma
companies, small specialized biopharmaceutical
companies from developed and developing
countries, etc.
14Establishment ofDedicated Research Centers
Source IFPMA, Septembre 2004
15Creation of a RD efforts database
- In September 2005, launch of a database
collecting all the health initiatives involving
the pharmaceutical industry to benefit the
Developing countries - A comprehensive list of both RD and Access
Initiatives - Accessible on the Internet (via the IFPMA
website) by the general public - Create an overall vision for industry activities
in addressing developing countries needs - Build a central depositary used to create new
collaborations and partnerships
16Public-Private Partnerships development (1)
- TDR The Special Program for Research and
Training in Tropical Diseases - and its Industry
Partner a long and fruitful collaboration
17Public-Private Partnerships development (2)
- Examples of Product Development PPPs for
Neglected diseases
Source IFPMA, Septembre 2004
18(No Transcript)
19FAC Project an innovative partnership against
Malaria
- For Malaria, new medicine needed to adress drug
resistance - WHO recommands the development of 4 Artemisine
Combination Therapies (ACT) - But, 2 combinations needed a new fixed-dose
combination - FAC Project
- A scientific partnership, coordinated by DNDi, to
develop fixed-dose combination of
Artesunate/Amodiaquine (AS/AQ) and
Artesunate/Mefloquine (AS/MQ) - A public-private Innovative partnership
Sanofi-Aventis DNDi - In 2006, a new medicine available
- Easy to use for adults and children
- Less expensive Target price 1
- Off patent
- WHO estimations 50 to 100 million of people
could received this treatement
20Results a growing RD pipeline
Source IFPMA, Septembre 2004
21Conclusions
- Public-private partnerships prove to offer the
most effective solution - Pharmaceutical companies increasing its
commitment in - Developing dedicated RD projects
- Establishing many health partnerships
- Bringing critical resources (products, money,
people) - Contributing in valuable cross-country experience
and expertise in health care delivery - Introducing a private sector management
philosophy that helps achieve needed results - Significant and promising global awareness
22Conclusions
- Therefore, any successful initiatives must
include - Political will
- Partners
- Infrastructure to get the medicines to patients
- Physicians training and patient education
- Proper diagnosis dispensing
- Quality control
- Proper dispensing
- Monitoring of outcomes